Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses

被引:40
作者
Currier, MA [1 ]
Adams, LC [1 ]
Mahller, YY [1 ]
Cripe, TP [1 ]
机构
[1] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Hematol Oncol, Cincinnati, OH 45229 USA
关键词
rhabdomyosarcoma; oncolytic virus; herpes simplex virus; NV1020; NV1066; G207; green fluorescent protein;
D O I
10.1038/sj.cgt.7700799
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Novel methods of local control for sarcomas are needed. We investigated the antitumor effect of two related herpes simplex virus (HSV) mutants, NV1020 and NV1066, on human rhabdomyosracoma cells and xenografts. Cell death correlated with virus replication and apoptosis in cultured cells and tumors. Complete regression was seen in all tumors <250 mm(3) following a single injection, yet only half of tumors >250 mm(3) showed a complete response. Fractionation of the virus dose into five injection sites did not increase transduction efficiency, transgene expression, or virus production, but did yield more widespread intratumoral distribution. Despite the same total dose of virus, improved control of large tumors was seen using fractionated injections as all large tumors ( 500 - 700 mm(3)) had durable, complete regression. Our data suggest that oncolytic HSVs may be useful for local control of bulky rhabdomyosarcoma tumors and that fractionated virus administration results in a more widespread virus infection and better tumor control. Therefore, strategies to maximize intratumoral virus distribution at initial delivery should be sought.
引用
收藏
页码:407 / 416
页数:10
相关论文
共 55 条
[1]   The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors [J].
Andreansky, SS ;
He, B ;
Gillespie, GY ;
Soroceanu, L ;
Markert, J ;
Chou, J ;
Roizman, B ;
Whitley, RJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (21) :11313-11318
[2]   Emerging cancer-targeted therapies [J].
Arceci, RJ ;
Cripe, TP .
PEDIATRIC CLINICS OF NORTH AMERICA, 2002, 49 (06) :1339-+
[3]   Viral oncoapoptosis of human tumor cells [J].
Aubert, M ;
Blaho, JA .
GENE THERAPY, 2003, 10 (17) :1437-1445
[4]   Modulation of apoptosis during herpes simplex virus infection in human cells [J].
Aubert, M ;
Blaho, JA .
MICROBES AND INFECTION, 2001, 3 (10) :859-866
[5]   Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer [J].
Bennett, JJ ;
Delman, KA ;
Burt, BM ;
Mariotti, A ;
Malhotra, S ;
Zager, J ;
Petrowsky, H ;
Mastorides, S ;
Federoff, H ;
Fong, YM .
CANCER GENE THERAPY, 2002, 9 (11) :935-945
[6]   Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses [J].
Bharatan, NS ;
Currier, MA ;
Cripe, TP .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2002, 24 (06) :447-453
[7]  
Borden EC, 2003, CLIN CANCER RES, V9, P1941
[8]   Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207) [J].
Carew, JF ;
Kooby, DA ;
Halterman, MW ;
Federoff, HJ ;
Fong, YM .
HUMAN GENE THERAPY, 1999, 10 (10) :1599-1606
[9]   COMPARISON OF GENETICALLY-ENGINEERED HERPES-SIMPLEX VIRUSES FOR THE TREATMENT OF BRAIN-TUMORS IN A SCID MOUSE MODEL OF HUMAN-MALIGNANT GLIOMA [J].
CHAMBERS, R ;
GILLESPIE, GY ;
SOROCEANU, L ;
ANDREANSKY, S ;
CHATTERJEE, S ;
CHOU, J ;
ROIZMAN, B ;
WHITLEY, RJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (05) :1411-1415
[10]  
Cinatl J, 2003, CANCER RES, V63, P1508